Valuation: Abbott Laboratories (Pakistan) Limited

Market Cap 96.91B 350M 314M 287M 262M 494M 32.92B 509M 3.46B 1.38B 17.57B 1.31B 1.29B 55.46B P/E 2024
23.2x
P/E 2025 -
Enterprise Value 96.91B 350M 314M 287M 262M 494M 32.92B 509M 3.46B 1.38B 17.57B 1.31B 1.29B 55.46B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
19.95%
Yield 2024 *
-
Yield 2025 3.81%
1 day-1.04%
1 week+2.40%
Current month+2.40%
1 month+7.04%
3 months+6.39%
6 months+11.02%
Current year-5.74%
1 week 943.3
Extreme 943.3
1,025.6
1 month 907.12
Extreme 907.12
1,025.6
Current year 821
Extreme 821
1,274
1 year 821
Extreme 821
1,274
3 years 385
Extreme 385
1,310
5 years 330
Extreme 330
1,310
10 years 302.1
Extreme 302.1
1,310
Manager TitleAgeSince
Chief Executive Officer - 01/04/2016
Director of Finance/CFO - 01/11/2019
Chief Operating Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member - 01/03/2009
Director/Board Member - 04/06/2014
Chairman - 30/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
-1.04%+2.40%-10.28%+142.16% 350M
-0.79%-4.48%+46.48%+118.69% 1,206B
+1.43%+1.11%+48.05%+83.72% 665B
+1.07%-1.21%+32.92%+105.10% 515B
+2.14%+0.33%+42.88%+67.37% 381B
-0.14%-1.87%+70.06%+40.55% 362B
+0.89%+2.19%+31.51%+59.43% 307B
+1.20%+1.92%+7.62%+35.36% 289B
+0.03%-1.20%+43.79%+68.49% 249B
-0.41%-2.22%+40.43%+114.24% 207B
Average +1.04%-1.06%+35.35%+83.51% 418.01B
Weighted average by Cap. +1.23%-1.96%+42.53%+86.71%

Financials

2024 2025
Net sales 68.18B 246M 221M 202M 184M 347M 23.16B 358M 2.43B 971M 12.36B 925M 905M 39.02B 75.4B 272M 244M 223M 204M 384M 25.62B 396M 2.69B 1.07B 13.67B 1.02B 1B 43.15B
Net income 5.23B 18.92M 16.97M 15.51M 14.15M 26.67M 1.78B 27.51M 187M 74.53M 949M 71.01M 69.48M 3B 7.97B 28.79M 25.82M 23.6M 21.54M 40.59M 2.71B 41.87M 284M 113M 1.44B 108M 106M 4.56B
Net Debt - -
Projected Income Statement - Annual - Abbott Laboratories (Pakistan) Limited
Logo Abbott Laboratories (Pakistan) Limited
Abbott Laboratories Pakistan Limited is engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. The Company operates through four segments: Pharmaceutical, Nutritional, Diagnostic, and Others. It offers treatment options for a number of areas, including the digestive system, heart health, women’s health, respiratory illness, central nervous system/pain and influenza vaccines. Its nutritional brands include Similac, PediaSure, Pedialyte, Ensure, and Glucerna. It offers tests and diagnostic tools, medical diagnostic instruments, automation and informatics solutions for hospitals, reference labs, blood centers, emergency departments, physician offices and clinics. The Company’s easy-to-use test strips require only tiny blood samples while its meters provide results and reports.
Employees
1,380
Date Price Change Volume
06/11/26 PKR 989.89 -1.04% 4,509
05/11/26 PKR 1,000.30 +3.18% 41,385
04/11/26 PKR 969.50 +0.98% 32,715
03/11/26 PKR 960.06 +0.17% 2,173
02/11/26 PKR 958.42 -0.86% 1,867
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Abbott Laboratories (Pakistan) Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
989.89
Average target price
-

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Abbott Laboratories (Pakistan) Limited
  1. Stock Market
  2. Stocks
  3. ABOT Stock